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Summary
Background:

Material/Methods:

Toxoplasma is an important source of foodborne hospitalization with no safe and effective therapy against chronic or congenital Toxopalsmosis. Atovaquone is a drug of choice but not approved
for use in congenital Toxoplasmosis. We hypothesized atovaquone to be safe and effective against
feto-maternal Toxoplasmosis.
Programmed pregnant mice were i.p. infected with 50–2400 Tachyzoites from Type II strain (clone
PTG). Dams were treated daily with atovaquone or sham and monitored for pain, and complications.

Results:

Dams developed pain related abdominal hypersensitivity (allodynia) to mechanical stimuli in a
Tachyzoites dose dependent manner. Infected dams were anemic and exhibited ascities and severe hepatitis (score 3.6±0.01 on scale 0 – normal to 4 – severe) with influx of inflammatory and
plasma cells, multinucleated dysplastic hepatocytes and necrosis. In addition, dams expressed mild
to severe pancreatitis with mononuclear cell invasion, loss of islets and necrosis. This was consistent with splenomegaly (X3 Fold), and massive infiltration of epithelioid cells and loss of germinal structure. Colon became significantly shortened in length (p<0.01) with semi-normal content.
Pathological manifestation included, shortening of crypts with numerous microabscess formations,
infiltration of lymphocytes, and macrophages. The severe clinical complications led to abortion
(50%), early birth (25%) or still birth (25%) consistent with the high dose of Tachyzoites inoculation. Atovaquone treatment partially but significantly protected the dams from the severity of hepatitis, splenomegaly, colitis, myocarditis, and pain related responses as well as fetal demise.

Conclusions:

This is a valuable model for therapeutic evaluation of feto-maternal Toxoplasmosis and gastrointestinal complications. Atovaquone protects dams and their fetuses against some infectious/inflammatory aspects of the disease.
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Background

Material and Methods

Toxoplasma gondii, an obligate intracellular protozoan, is an
important source of foodborne hospitalization. Toxoplasma
infects humans and animals, specifically in impoverish and
disadvantage populations. Toxoplasmosis in immunocompetent individuals is usually asymptomatic or manifested
as flu like syndrome, but outcomes can include severe impediment in immunocompromised hosts as well as fetuses leading to demise and death [1]. It is estimated that
1,500,000 cases of Toxoplasmosis occurs in the U.S.A each
year, and about 15% of these cases show clinical symptoms
[2]. Toxoplasmosis reactivation occurs primarily during
pregnancy and in AIDS and in immunocompromised individuals when cysts rupture. Congenital Toxoplasmosis
in humans as well as animals (e.g. sheep and goats) is initiated by the transplacental transmission of organisms during maternal infection [3]. The congenital transmission of
Toxoplasmosis was first reported in a 3 day old infant from
New York in 1939 [4], and the importance of maternal fetal transmission has long been recognized [5]. Congenital
Toxoplasmosis leads to spontaneous abortion, intrauterine
fetal death or severe congenital defects, such as encephalitis, hydrocephaly and chorioretinitis [6]. Toxoplasma invades the central nervous system (CNS) with adverse affect
in brain neuro-structural development and pathological
as well as psycho-behavioral alteration leading to mental
retardation [7–9]. More recently, maternal exposure to
Toxoplasma organisms has been linked to a potential increased risk for schizophrenic episodes and this hypothesis has received a significant media attention.

Toxoplasma gondii propagation

Current therapy against Toxoplasmosis includes atovaquone
(hydroxy-1,4-naphthoquinone) which is an FDA approved
treatment but not in use for congenital Toxoplasmosis [10].
Atovaquone has been proven to be effective against opportunistic diseases such as Pneumocystis carinii pneumonia [11],
malarial infections [12], and Babesia microti causative of human babesiosis [13,14]. So far, there is no safe and effective
therapy (FDA approved) against congenital Toxoplasmosis
or any drug capable of eliminating the persistent, chronic
Toxoplasma infection. Spiramycin alone or associated with
pyrimethamine-sulfadoxine are used to prevent transfer of
Toxoplasma from the actively infected mother to the fetus.
However, this approach is not always effective and associated with unwanted side effects [15–18].
The congenital Toxoplasmosis models are induced by the
oral inoculation of Toxoplasma cysts or Tachyzoites from
infected animals [19] or intraperitoneal injection of cysts
from ME49 strain [20]. Consequently, a simple and reliable
model for Toxoplasmosis induced feto-maternal complications is highly desirable to study the progression of disease
and to investigate the therapeutic modalities in the model.
The objectives of this study were to: a) to develop a fetal maternal model to present moderate to severe gastrointestinal Toxoplasmosis complications during the pregnancy for
the use in drug evaluation and b) to study efficacy of atovaquone against Toxoplasma infection in the model.
Therefore, it was hypothesized that atovaquone to be safe
and effective against feto-maternal complications as consequences of Toxoplasmosis in a murine pregnancy model.
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Type II isolates of Toxoplasma including ME-49 strain is predominantly discovered in human congenital Toxoplasmosis
[21]. For this study, Toxoplasma Tachyzoites from PTG
strain (ME-49, ATCC50841™) were originally cloned and
propagated [22] and kindly provided by Dr. Daniel Howe,
PhD, Maxwell H Gluck Equine Research Center, College
of Agriculture, University of Kentucky. Briefly, Tachyzoites
were cultured by serial passage in bovine turbinate cells
and maintained in minimum essential medium (MEM-RS,
HyClone Labs, Inc.) supplemented with 4% fetal clone III
(HyClone, Labs, Inc.), Penicillin/Streptomycin/Fungizone
(BioWhittaker, Inc.), and non-essential amino acids solution (HyClone, Labs, Inc.). Upon disruption of the host cell
monolayer, extracellular Tachyzoites were harvested and
purified from host cell debris by filtration through 3.0 µm
membranes. Tachyzoites were enumerated in a hemocytometer and suspended in phosphate buffer saline (PBS)
to the appropriate concentrations for inoculation. To ensure Tachyzoites viability, inoculums were given intraperitoneally (i.p.) in 100 µl volume and within 1 h of harvest.
Murine model
This investigation was conducted according to the guidelines and approved by the Institutional Biosaftey Committee
(IBC) and Institutional Animal Care and use committee
(IACUC) at University of Kentucky Medical Center which
is certified by the American Association of Accreditation of
Laboratory Animal Care (AAALAC).
On day 1 of programmed pregnancy, 9 weeks old CD1 mice
were purchased from Charles River Lab Inc. (Wilmington,
MA) and housed individually in micro-isolator cages in a
pathogen free environment. The room was maintained
at 22°C with a 12:12-hr light:dark cycle at the Maxwell H.
Gluck Equine Research Center Laboratory Animal Facility
at the University of Kentucky. Dams were fed irradiated rodent chow and sterilized drinking water ad libitum. After 5
days acclimation, dams were weighed and ear-punched for
appropriate identification.
To establish the model, dams were assigned into 6 animals
per each group, and injected with 100 µl of Tachyzoites from
0–50–100 and then 300–600–1200–2400 organisms (at proportion of about 2 fold increments) given i.p. using 0.5 ml
insulin syringes. Control dams (group 7) received 100 µl
sham vehicle injection with sterile PBS. Animals were monitored daily 3 times for physical appearance, distress, pain,
and vaginal discharge to detect abortion, early delivery, or
gastrointestinal complications [23]. The experiment was
terminated on gestation day 16 before the possible early or
premature birth to study the feto-maternal complications.
For further drug evaluation we chose a cutoff dose of 600
Tachyzoites inoculations where animals developed a moderately severe feto-maternal Toxoplasmosis.
Atovaquone treatment
Atovaquone is currently used as a drug of choice against
Toxoplasmosis but not tested in pregnancy. In order to study
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efficacy of atovaquone against Toxoplasmosis in pregnancy,
dams were divided into 2 groups. One group received atovaquone (hydroxy-1,4-naphthoquinone) incorporated into
daily diet as indicated in our previous publications [13,14].
Control group received sham treatment (inert talcum powder). The treatment was initiated on Day 5 of pregnancy
and continued until day 16 when dams were euthanatized.
On day 8 of pregnancy dams on treatment or sham control arms were further divided into 3 subgroups of 6–8 animals and were inoculated each with 0 (PBS), 300, or 600
Tachyzoites. Pregnant animals voluntarily consumed the
diet with no major changes in their appearance, food consumption or weight/loss gain.

Grade 0 – Represented no detectable lesions, no degeneration, infiltration of inflammatory cells, normal
tissue appearance.
Grade 1 – Focal infiltration of inflammatory cells in the tissue, and hepatocytes degeneration.
Grade 2 – Mild multi-focal infiltration of inflammatory cells,
and hepatocytes degeneration.
Grade 3 – Moderate multi-focal infiltration of inflammatory cells, and hepatocytes degeneration.
Grade 4 – Severe diffuse infiltration of inflammatory cells,
and necrosis.

Sample collection

Giemsa is a delicate polychromatic stain that reveals a fine
nuclear detail of Toxoplasma organisms. Giemsa stain contains Methylene Blue Azure Basic dyes combined with Eosin
Acidic dyes. The deparaffinized slide sections were placed
into the polychromatic Giemsa (40drops/50ml distilled water) to stain nuclei of the Toxoplasma organisms and to permit
differentiation among the cells. Then, the slides were depreciated in 1% Glacial Acetic Acid, dehydrated in alcohol and
xylene series and mounted in synthetic resin on the slides.

At the end of study dams were weight and euthanatized using
Co2 inhalation. Immediately, their chests were opened and
blood from right ventricle collected into microtainer (BD
Biosource, Rockville, MD). Sera were separated and stored
frozen at –80°C. The splenic weight and length were recorded. Organs including liver, pancreas, spleen, heart and uterus were excised and weighed. Sections of these tissues were
flash frozen in liquid nitrogen and stored at –80°C for future studies. Live fetuses were removed from uteri, counted, weighed and their length measured from crown to the
base of the tail using a digital caliper.
Histopathological Examination
Colonic tissue and H&E staining
Colonic tissues were flushed with PBS (pH 7.2) and a portion from proximal and distal colonic tissue was fixed in
10% neutral formalin for histological examinations. The
remainder was snap-frozen in liquid nitrogen and stored
at –80°C. The formalin fixed sections were processed and
stained with hematoxylin and eosin (H&E), and slides evaluated by Ziess light microscopy. Severity of colitis was assessed
with a histological semi-quantitative grading score and performed in a blinded fashion. The scores were based on histopathological features with a numeric value (0 – normal
to 4 – severe) assigned according to the tissue involvement
[24] that corresponded to either of the following criteria:
Grade 0 – No detectable lesions, no inflammatory cells, normal mucosal appearance.
Grade 1 – Focal inflammatory infiltrate in the mucosa.
Grade 2 – Mild multi-focal inflammation with moderate expansion of the mucosa.
Grade 3 – Moderate multi-focal inflammation with moderate expansion of the mucosa.
Grade 4 – Severe diffuse inflammation with crypt epithelium disruption and ulceration.
Hepatic tissues
A small portion of the right lobe from hepatic tissues was
placed in cassettes and fixed with 10% neutral buffered
formalin. The specimens were dehydrated and embedded in paraffin, and tissue sections of 5µm were stained by
Hematoxylin Eosin (H&E). Each slide was evaluated under light microscopy [25]. Hepatic lesions were graded on
a scale of 0 to 4+, based on degeneration, inflammation,
and necrosis as follows:

Giemsa staining

Immunohistochemical (IHC) staining
IHC was performed using Dalo EnVision+ System-HRP
(DAB) kit. Anti-Toxoplasma antibody and IHC procedure
were kindly provided by David S. Lindsay, PhD at University
of West Virginal. Briefly, paraffin-embedded sections were
cut, deparaffinized with xylene, rehydrated in alcohol baths,
washed in PBS and 0.1% BSA, quenched endogenous peroxidase activity by incubating in 3% hydrogen peroxide in
methanol for 30 min, then blocked with rabbit serum (Dako
#N1699), for 30 min. The sections were incubated with polyclonal anti-Toxoplasma antibody, diluted 1:500 for 90 min
and developed with DAB-Chromogen (Dako Carpenteria,
CA) for about 5 min until signal developed. Slides were
subsequently counterstained with hematoxylin then ammonia treated and dehydrated stepwise through alcohol,
and cleared with xylene.
Behavioral test: assessment of pain related mechanical
allodynia by testing abdominal withdrawal threshold
Abdominal withdrawal responses to mechanical stimuli were
quantified with von Frey monofilaments (Semmes-Weinstein
Anesthesiometer Kit, model #18011, Wood Dale, IL) according to our previous publication with some modification [26]. Briefly, mice were placed into plastic enclosures
on the custom made screen meshed platform. The monofilament range used for this study included 5 different intensities corresponding to (hair diameter) gram force [(4.08)
1.0 g; (3.61) 0.4 g; (3.22) 0.166 g; (2.83)0.07; (2.36) 0.02g
forces]. Testing for mechanical stimulation was performed
on the first and the last day of treatment. A single trial consisted of 5 applications of the each filament used once every 6 seconds to allow the dam to cease any response and
return to an inactive position. Mean values of the percentage of responses of the abdominal withdrawal to each filament (mean withdrawal/5 ×100) were used as % scores in
this study. This behavioral test reflected basal level for reflex score and any possible sensory changes observed in
the treated mice. Total 4 dams were tested per each group.
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Figure 1. Percent pain related abdominal response
to Von Frey mechanical stimuli to
0.166 GM force. (A) Dose dependent
abdominal response from dams
infected with Tachyzoites (T-600 to
T-2400) compared to normal Controls
demonstrating increased hypersensitivity
to stimuli. (B) Atovaquone treatment
ameliorated hypersensitivity to stimuli
(allodynia) in infected dams (T-600).
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Statistical analysis
Results are expressed as mean ±SEM unless otherwise stated. Data was evaluated with ANOVA followed by appropriate post hoc test (Tukey compared all pairs) using GraphPad
Instat version 3 for Windows (GraphPad Software, San Diego,
CA). Statistical significance was set at p<0.05.

Results
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40
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10
0

Control

Model for feto-maternal Toxoplasmosis
To establish the model, dams were infected with single inoculum of PTG strain Tachyzoites ranging from 100 to 2400
during the 2nd trimester of pregnancy. Dams infected with
low dose (T-50) showed no significant clinical symptoms.
While, those infected with higher number of Tachyzoites
developed moderate to severe clinical complications in a
dose dependent manner leading to abortion (4/8, 50%),
early birth (1/4, 25%) or still birth (1/4, 25%).
Pain related abdominal response to stimuli
Infected dams showed significant increases in abdominal
response to the mechanical stimuli (allodynia) with von
Frey monofilaments. The elevated hypersensitivity showed a
Tachyzoites dose dependent response with about 4 fold increments in dams receiving the highest dose (T-2400, p<0.001) representing the most severe reaction to the stimuli (Figure 1A).
Excess body weight gain
Both uninfected normals as well as infected dams gained
weight. However, dams infected with high doses of
Tachyzoites (T-1200 to T-2400) showed a more severe edema, ascities, and hydrothorax with a significant excess body
weight gain leading to fetal abortion or mummified embryos.
Ascities consisted of a bright to bloody fluid and was mainly noted in the peritoneal and chest cavities (pneumothorax) and correlated with the higher doses of Tachyzoites.
Anemia
Infected dams became anemic with pale mucosa (hematocrit: p<0.01 T-2400 Figure 2), in addition to hydrothorax
and ascities. This was consistent with the splenomegaly with
about X3 fold increases in splenic weight (Figure 3A) and
length (Figure 3C) in the infected dams mainly due to the
scavenging infected cells by the splenic tissues and the severe immune response to infection, demonstrating massive
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<0.01

T-600
T-1200
Hematocrit

T-2400

Figure 2. Infected dams had pale mucosa and became anemic as
demonstrated by significant decreases in hematocrit values
in a dose dependent manner (controls vs. T-600 p<0.05,
Controls vs. T-1200 and T-2400 p<0.01).
infiltration of epithelioid cells, and engulfed infected macrophages in conjunction with loss of germinal structure in
spleen in a dose dependent manner.
Hepatic and pancreatic pathology
Hepatic tissue became pale in color and weight increased
due to inflammation. Infected dams developed hepatitis
(scale 0 – normal to 4 – severe, T-1200=3.6±0.1 p<0.001)
presenting portal lobular influx of inflammatory and plasma cells, multinucleated “dysplastic” hepatocytes and mild
to severe hepatic necrosis. These lesions were in a dose dependent manner and correlated with the number of inoculated Tachyzoites (Figure 4A). In addition, dams showed
mild to moderately severe pancreatitis with mononuclear
cell invasion and loss of islets (not shown).
Cardiac pathology
Infected dams developed a mild to moderate myocardial necrosis, fibrin deposit, and infiltration of inflammatory cells
(Figure 5). Small pseudocysts to elongated cysts were detected with a few to numerous bradyzoites embedded with aggregates of macrophages, plasma and monocytes infiltration.
The cysts and occasional free organisms were detected in
the heart, hepatic, and splenic tissues which were confirmed
with Giemsa and immunohistochemical techniques (IHC).
Fetal weight and length
Dams infected with low doses of Tachyzoites (T-50 to
T-300) did not show a significant differences between the
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Figure 3. Splenic weight (A) and length (C) significantly increased in infected dams and partially but significantly improved in atovaquone treated
animals (B, D, p<0.05).
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appearance, fetal number, weight and length of the live fetuses (p>0.05, NS). In contrast those dams inoculated with
the high doses (T-1200 toT-2400) developed more progressive disease leading to abortion, or intrauterine fetal demise, and still birth (Figure 6A). Occasionally organisms
were detected in the uterine tissue from infected dams
with high dose of Tachyzoites by means of IHC (Figure 6B).
Fetal weight (Figure 7A) was significantly affected in infected dams in a dose dependent manner leading to retarded
and/or fetal loss.

Figure 4. H&E stained sections from hepatic tissues
were scored from normal (0) to severe
(4) hepatitis (A). Atovaquone treatment
significantly ameliorated the lesions in
dams and protected against hepatitis as
consequences of Toxoplasmosis (B).

Autovaquone

Figures 5. H&E stained cardiomyocytes from
infected Dam and cardiac weight.
Infected dams developed mild to
moderate myocarditis (A) with
infiltration of inflammatory cells (H&E
staining). Cardiac weight increased
in infected dams and atovaquone
treatment attenuated pathological
inflammatory response and excess
weight (B).

Therefore, based on the above obtained data, a cutoff at
600 Tachyzoites (T-600) per inoculum was established to induce a moderately severe feto-maternal Toxoplasmosis in
the model for further drug evaluation.
Atovaquone therapy in pregnancy model
Overall, atovaquone treated uninfected control dams showed
no major differences compared to untreated normal controls (sham injected) for the parameters measured, and
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A

A

Figure 6. Uteri from infected (red arrow) and
uninfected (blue arrow) dams (A) similar
to atovaquone treated ones (not shown
here). Immunohistochemical staining
demonstrating infected uteri. Arrows
point at the organisms (B).
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Figure 7. Fetal weight significantly decreased in
a dose dependent response due to the
infection (A). Atovaquone treatment
returned the fetal weight to a normal
value (B).
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Table 1. Dams were infected with Toxoplasma Tachyzoites (T-600) on pregnancy and treated with atovaquone daily.
Tissues from Dams

Control

Infected

Infected + Treated

P< value

Body Weight gain (g)

14.2±0.6***

22.8±1

22.5±0.9

***<0.001

Colonic length (cm)

10.25±025**

8.6±0.27

8.6±0.5

**<0.01

Colonic weight/ atrophy (mg)

250±10**

200±10** *

230±10*

**<0.01, *<0.05

Hematocrit (%)

44.5±1.2*

37±1.4

34.7±3.3

*<0.05

Utri weight (g)

11.6±0.5*

13.9±0.7*

12.8±1

*<0.05

Hepatic weight (g)

,

1.78±0.24** *
,

3.4±0.13**

3.1±0.34*

**<0.01, *<0.05

P value – * <0.05; ** <0.01; ***<0.001.
kept a normal status. Whereas, atovaquone treated and infected dams showed no significant improvement in their
excess body weight gain compared to infected (untreated)
animals (Table 1).
Pain related abdominal response to stimuli and atovaquone
therapy
Infected dams (T-600) showed a significant pain related
abdominal hypersensitivity (p<0.05) to mechanical stimuli
(Figure 1B). In contrast, atovaquone treatment attenuated
this neuropathological reactions to a normal level (p<0.05)
indicating efficacy of atovaquone to ameliorate pain related clinical symptoms of infection/inflammatory induced
hypersensitivity (Figure 1B).
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Anemia, splenomegaly and atovaquone therapy
Atovaquone did not improve hematocrit or anemia in infected and treated dams (Table 1). Infected dams developed enlarged fragile splenic tissues. In contrast, atovaquone therapy partially but significantly attenuated splenomegaly and
the pathological increases in the splenic weight and length
in infected dams (Figure 3B, D).
Pathology and atovaquone therapy
Hepatitis
Infected dams (T-600) developed moderately severe hepatic lesions (score of 3.3±0.01 P<0.001) presenting, scattered dysplastic hepatocytes and moderate to severe hepatic

Med Sci Monit, 2012; 18(9): BR337-345

necrosis and excess weight due to infiltration of inflammatory cells (p<0.01) (Figure 4). Atovaquone partially but
significantly attenuated these pathological manifestations
and improved hepatic structural integrity (score 2.8±0.1
p<0.05) (Figure 4B) as well as the excess hepatic weight
(p<0.05) (Table 1).
Colonic pathology
Colonic tissues from infected dams (T-600) were significantly
shortened in length (10.4±0.2 vs. infected 8.7±0.6 cm p<0.01)
and decreased in weight (p<0.01) presumably through the
mechanism of sloughing off of the brush boarder in infected
dams (Table 1). Colonic pathology manifested with shortening of crypts with numerous microabscess formations, and
infiltration of inflammatory cells, including lymphocytes,
and macrophages with few scattered neutrophils detected in the mucosal area. Atovaquone extensively protected
dams from colonic inflammatory and necrotic/atrophic responses to the infection (p<0.05). In addition, a mild to severe pancreatitis was diagnosed in infected dams (T-600 vs.
Normal p<0.05) with invasion of mononuclear cells and loss
of islets (not shown). Similarly, atovaquone treatment partially but significantly protected the dams from these pathological and inflammatory aspects of the GI Toxoplasmosis.
Cardiac pathology
Infected dams developed a mild myocardial necrosis, fibrin
deposit, and infiltration of inflammatory cells as shown in
H&E staining (Figure 5). Small to elongated cysts were detected with a few to numerous bradyzoites embedded with
aggregates of macrophages and plasma and monocytes infiltration. This was consistent with the detection of cysts and
free organisms in the heart, hepatic as well as the splenic
tissues which were confirmed with Giemsa and IHC techniques. Atovaquone significantly improved myocardial pathology and excess cardiac weight (Figure 5B).
Fetal weight
Infected dams (T-600) showed fetal retardation and sporadic cases of still birth. In contrast, atovaquone treatment
protected nested fetuses in uterine from weight loss, retardation and demise (Figure 7B).

Discussion
Two billion people worldwide are predicted to have
Toxoplasmosis, frequently with unknown lifelong health
consequences [28]. Toxoplasma is considered as the 3rd major cause of foodborne diseases’ hospitalization and death
in the U.S.A [27]. Toxoplasmosis can have mild effects on
immunocompetent to very severe pathological damage in
congenital transmission. Congenital Toxoplasmosis is caused
by a reactivation, or as an acquired infection during pregnancy is known to be associated with an altered balance
of immune response rather than direct noxious actions of
the pathogen [3–5]. Feto-maternal Toxoplasmosis results
in an extensive immune and inflammatory response to the
organisms in the gastrointestinal tissues with a low number
of pathogenic burdens as demonstrated in this pregnancy model. Indeed, managing the inflammation is vital in
order to prevent damage to the host and the nested fetus
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during the infection. While, uncontrolled inflammatory response in Toxoplasmosis can be fatal during the pathogenic clearance [29].
Our findings with this murine system support the model in
which fetal health is compromised by the invasion of pathogens and encountered inflammatory responses from infected
dam through the mechanism of transplacental transmission
and in a dose dependent manner. A recent study indicates that
a dose of 10,000 bradyzoites or 100 oocysts of the Prugniaud
strain (Type II) to cause 50% congenital infection of the rat
litters. In contrast, lactation alone did not support transmission of infection from dams to the neonates [19].
Pregnant women become infected by ingestion of oocysts contaminated food, or consumption of cysts harboring bradyzoites-infected meat. Additionally, transplacental
transmission is acquired by the reactivation of the chronic
or latent infection due to the stressors including pregnancy and immunosuppressors. In any circumstances, whether
oocysts, cysts, (or Tachyzoites) are the origin of the infection the organisms transform to Tachyizoites and replicate
in the organs to cause the infection. Then the Tachyzoites
are required to bypass the transplacental blood barrier to
invade the fetus and to compromise the embryonic developmental process.
The current model bypasses the requirement for oral passage and a large number of organisms by using direct intraperitoneal inoculation to cause feto-maternal Toxoplasmosis.
This model imitates well the Toxoplasma reactivation or contaminated blood transfusion and organ transplantation, and
uses a fewer organisms than those required for an oral infection. Additionally, this model eliminates the use of extra
animals (mice or cats) to develop cysts or oocyts. Therefore,
the present model mimics well the process of the intrauterine infection, and evades the oral inoculation and the need
for a large numbers of the organisms.
The majority of Toxoplasma strains so far isolated from
North America and Europe belong to three clonal lineages I–III, of which types I and II are associated with congenital Toxoplasmosis [30]. For this study, we used type II
Tachyzoites from PTG strain (ME-49) originally cloned and
propagated [22] to initiate the infection. ME-49 genotype
II strain is most frequently associated with the human disease including congenital Toxoplasmosis [21,30–33] and
used in this study to develop the feto-maternal model for
the drug evaluation.
Thus far, there is no safe and effective or FDA approved
therapy against congenital Toxoplasmosis or any drug capable of eliminating the persistent, chronic infection [10].
Atovaquone is a drug of choice against Toxoplasmosis but
not yet approved for the use in pregnancy or small children.
As shown in this study, atovaquone was effective against complications in the model and limited the inflammatory responses to Tachyzoites infection in organs such as cardiac,
spleen, hepatic and colonic tissues and therefore protected the fetuses and the dams from the infection.
Atovaquone has been shown to be effective against
Tachyzoites and cyst forms of Toxoplasma [12], Pneumocystis
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carinii [11], Plasmodium Falciparum (12) and B. microti [13,14]
organisms. Atovaquone is known to inhibit parasite and fungal respiration by binding to the ubiquinol oxidation site of
cytochrome bc1 complex [34] by affecting the mitochondrial function and collapsing their membrane [35]. The radiolabelled tracing in man has proven that atovaquone mainly
attaches to the plasma protein (99%) with a half life of 1.5
to 3 days with 2 peaks; the 1st peak appears at 1–8 h and 2nd
in 1–4 days after a single oral dose in human volunteers. In
addition, surgical biliary tube insulation in patients demonstrated that atovaquone is exclusively (94%) excluded
from the body through the feces and it is not metabolized
by humans [36]. Indeed, mice with a targeted gene mutation in the interferon regulatory factor 8 when latently infected with Toxoplasma, developed reactivated encephalitis,
and those treated with atovaquone were protected against
encephalitis and death [37]. Furthermore, atovaquone
treatment was proven to be superior to the standard therapy with pyrimethamine plus sulfadiazine or combination
of pyrimethamine plus clindamycin based on the inflammatory responses in the brain parenchyma, and the number of the organisms located in the brain in a mice [37].
In addition, atovaquone was detectable in sera, brains, livers, and lungs from infected mice using high pressure liquid chromatography (HPLC) and Mass Spectroscopy [37].
Generally, Toxoplasma disseminates from the gut throughout the body, and the organisms seek refuge in the muscular tissue and CNS in cysts forms during the dormant stage
[38]. It is known that extracellular Tachyzoites readily infect the host leucocytes, monocytes and dendritic cells and
expliting the host cells as “Trojan Horse” a) to disseminate
throughout the body and to cross the placenta [39] as well
as the blood brain barrier and b) to provide protection
against host immune defense [40].
In this investigation, the model well mimicked the disease
in the human pregnancy and atovaquone had a limited but
significant protective effect against gastrointestinal complications in these animals. Here, dams demonstrated significant excess weight gain (p<0.001) due to the inflammatory response to the infection. This is in accord with a recent
retrospective cohort study in 194 infected pregnant women who gained more weight when compared to 785 uninfected moms (P<0.001) [41]. However, atovaquone had
minor effect on the excess body weight gain in this model.
Thus, the feto-maternal and GI complications described
here permitted us to evaluate the efficacy of atovaquone in
this Toxoplasmosis pregnancy model. Atovaquone proved
to be fairly safe and to protect against inflammatory aspects
of the feto-maternal progression of Toxoplasmosis. These
findings warrant further functional, biochemical and molecular mechanistic studies in the fetal development, and
related syndrome and the use for development of new and
effective therapies.

Conclusions
This model can be used for therapeutic evaluation in fetomaternal Toxoplasmosis and gastrointestinal complications.
This study proves that atovaquone protects against some
inflammatory aspects of gastrointestinal and feto-maternal
Toxoplasmosis in this model.
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